Barr Names G. Frederick Wilkinson President and COO of Duramed Pharmaceuticals, Inc.
Paul M. Bisaro Named President, Barr Pharmaceuticals, Inc.
Barr Pharmaceuticals, Inc. announced that G. Frederick Wilkinson has agreed to join the Company as President and Chief Operating Officer of Duramed Pharmaceuticals, Inc., Barr's proprietary products subsidiary. In this position, Wilkinson will be responsible for managing all aspects of the Company's proprietary operations.
The Company also announced that Paul M. Bisaro has been promoted to the newly created position of President and Chief Operating Officer of Barr Pharmaceuticals, Inc. and that Wilkinson will report to Bisaro. In his new capacity, Bisaro will be responsible for coordinating the activities of Barr's proprietary and generic businesses and will continue to serve as President of Barr Laboratories, Inc., Barr's generic subsidiary. Bisaro joined the Company in 1992 as General Counsel. He was named President and COO of Barr Laboratories in 2001.
Wilkinson joins Duramed Pharmaceuticals from Columbia Laboratories where he served as Chief Executive Officer, President and a member of the Board of Directors since 2001. From 1996 to 2001, he worked at Watson Pharmaceuticals, where he was Chief Operating Officer and Senior Vice-President. Prior to joining Watson, he spent sixteen years at Sandoz Pharmaceutical Corporation in numerous senior managerial positions of increasing responsibility. Wilkinson received his M.B.A. from Capital University in 1984 and a B.S. in Pharmacy from Ohio Northern University in 1979. He began his career as a Staff Pharmacist at Riverside Methodist Hospital in Columbus, Ohio.
Other news from the department people
